Aviation Medication Transparency Act of 2024
Latest Action
Referred to the Subcommittee on Aviation.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Aviation Medication Transparency Act of 2024 is a bill introduced in the 118th Congress aimed at increasing transparency regarding medications related to aviation. While the official summary and full bill text are not available, the bill's title and policy area suggest it focuses on disclosure or regulation of medications that may impact aviation safety or operations. The bill was referred to the Subcommittee on Aviation but ultimately failed or expired without further legislative action.
This bill sought to enhance transparency about medications in the aviation sector but did not advance beyond early committee referral and expired in the 118th Congress.
- Introduced in the House during the 118th Congress as H.R. 9243.
- Focused on transportation and public works, specifically aviation-related medication transparency.
- Referred to the Subcommittee on Aviation on August 3, 2024, but did not progress further.
['Aviation industry stakeholders including pilots and airlines', 'Federal aviation regulatory bodies', 'Passengers and the general public concerned with aviation safety']
['Lack of available full text limits understanding of specific regulatory or enforcement mechanisms.', 'Potential costs or administrative burdens related to implementing medication transparency requirements are unknown.', 'Unclear authority or oversight provisions due to missing bill details.']
The bill was introduced in the House and referred to a relevant subcommittee but did not advance, indicating limited legislative momentum. The absence of a summary or full text in public records restricts detailed analysis of its legislative intent or support.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, increased medication transparency could influence aviation safety protocols and pilot health monitoring.', 'Potential administrative impacts on airlines and regulatory bodies managing compliance and reporting.', 'Possible effects on pharmaceutical disclosure practices related to aviation personnel.']
The absence of a full bill text and official summary limits transparency and public understanding of the bill's provisions and potential impacts. The bill's failure to advance beyond subcommittee referral highlights the importance of tracking legislative progress to assess government responsiveness to aviation safety and health issues.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.